Read by QxMD icon Read

"early rheumatoid arthritis"

A L Fedele, L Petricca, B Tolusso, S Alivernini, S Canestri, C Di Mario, S L Bosello, G Ferraccioli, E Gremese
OBJECTIVES: To define baseline clinical and immunological characteristics [anti-citrullinated peptide antibodies (ACPAs), immunoglobulin M (IgM)- and IgA-rheumatoid factor (RF), and interleukin-6 (IL-6) levels] involved in determining baseline erosiveness, outcome, and radiographic progression among seropositive and seronegative early rheumatoid arthritis (ERA) patients. METHOD: The 408 ERA patients enrolled in the study were monitored every 3 months according to the treat-to-target strategy...
March 15, 2018: Scandinavian Journal of Rheumatology
Karin Britsemmer, Dirkjan van Schaardenburg, Maarten Boers, Diederik De Cock, Patrick Verschueren, Helga Radner, Josef S Smolen, Lilian van Tuyl
OBJECTIVES: In 2011 an ACR/EULAR collaboration developed new remission definitions for RA. In the present study, we evaluated the prevalence and predictive validity of these new ACR/EULAR remission criteria in 4 different European early rheumatoid arthritis cohorts. METHODS: Data from a tot al of 722 patients with early RA were analysed. Presence of remission at 6 months, as defined by one of the 4 proposed ACR/EULAR remission definitions was used to predict good functional and radiological outcome between 1 and 2 years of follow-up...
February 26, 2018: Clinical and Experimental Rheumatology
D Rekalov, A Prytkova, R Kulynych, G Protsenko, V Protsenko
Objective of the study layed in assessment of the pathophysiological relation between cell-mediated immunity (tumor necrosis factor-alpha (TNF-α) inflammatory cytokine) activation and renal dysfunction in the patients with early rheumatoid arthritis. We analyzed the data from 35 early rheumatoid arthritis (RA) patients of average age of 50,71±2,25 years (ranged 18-76 years, 80% of women) with 9,21±0,43 months mean duration of the disease by the time of the study initiation. Urine and blood tests were performed to verify the main indicators of kidney function and inflammation cytokines significant interaction...
January 2018: Georgian Medical News
Sandra L Goss, Cheri E Klein, Ziyi Jin, Charles S Locke, Ramona C Rodila, Hartmut Kupper, Gerd-Rudiger Burmester, Walid M Awni
PURPOSE: Methotrexate (MTX) and adalimumab are well-recognized treatments of rheumatoid arthritis (RA), the efficacy of which may be driven by intracellular polyglutamates (PGs). The aim of this analysis was to characterize MTX PG concentrations and adalimumab pharmacokinetics in the CONCERTO trial. In addition, the relationships between MTX dose/pharmacokinetics, adalimumab pharmacokinetics, and efficacy were evaluated. METHODS: CONCERTO was a double-blind, parallel-arm study in patients with early RA randomized to adalimumab 40 mg SC every other week plus blinded MTX 2...
February 2018: Clinical Therapeutics
Iria V Seoane, Carmen Martínez, Rosario García-Vicuña, Ana M Ortiz, Yasmina Juarranz, Vanessa C Talayero, Isidoro González-Álvaro, Rosa P Gomariz, Amalia Lamana
We previously reported that early arthritis (EA) patients with low vasoactive intestinal peptide (VIP) serum levels demonstrate a worse clinical disease course. In this study, we analysed whether variants in the VIP gene correlated with its serum levels and clinical EA parameters. The VIP gene was sequenced in patients with extremely high/low VIP levels, measured by enzyme immunoassay. Sixteen single nucleotide polymorphisms (SNPs) were differentially distributed between both groups, which were subsequently genotyped in two patients' sets...
February 1, 2018: Scientific Reports
G A Versteeg, L M M Steunebrink, H E Vonkeman, P M Ten Klooster, A E van der Bijl, M A F J van de Laar
Patients in real life may differ from those in clinical trials. The aim of this study is to report 5-year outcomes of a continuous treat-to-target (T2T) approach in patients with rheumatoid arthritis (RA) in daily clinical practice. In the Dutch RhEumatoid Arthritis Monitoring cohort, all patients with a clinical diagnosis of RA were treated according to a protocolled T2T strategy, aimed at 28-joint Disease Activity Score (DAS28) < 2.6. Outcomes were percentages of patients in distinct levels of disease activity, mean course of DAS28 and prevalence of sustained (drug-free) remission...
February 1, 2018: Clinical Rheumatology
D F Ten Cate, J W G Jacobs, W A A Swen, J M W Hazes, M H de Jager, N M Basoski, C J Haagsma, J J Luime, A H Gerards
BACKGROUND: At present, there are no prognostic parameters unequivocally predicting treatment failure in early rheumatoid arthritis (RA) patients. We investigated whether baseline ultrasonography (US) findings of joints, when added to baseline clinical, laboratory, and radiographical data, could improve prediction of failure to achieve Disease Activity Score assessing 28 joints (DAS28) remission (<2.6) at 1 year in newly diagnosed RA patients. METHODS: A multicentre cohort of newly diagnosed RA patients was followed prospectively for 1 year...
January 30, 2018: Arthritis Research & Therapy
Doyt L Conn, Athan Tiliakos, Gaobin Bao, Shuling Liu, Kirk A Easley
One of the author's name on this article was incorrectly spelled as "Shuling Li". The correct spelling is "Shuling Liu" and is now presented correctly in this article.
January 29, 2018: Clinical Rheumatology
Claudio Carini, Ewan Hunter, Aroul S Ramadass, Jayne Green, Alexandre Akoulitchev, Iain B McInnes, Carl S Goodyear
BACKGROUND: There is a pressing need in rheumatoid arthritis (RA) to identify patients who will not respond to first-line disease-modifying anti-rheumatic drugs (DMARD). We explored whether differences in genomic architecture represented by a chromosome conformation signature (CCS) in blood taken from early RA patients before methotrexate (MTX) treatment could assist in identifying non-response to DMARD and, whether there is an association between such a signature and RA specific expression quantitative trait loci (eQTL)...
January 29, 2018: Journal of Translational Medicine
Jeffrey A Sparks, Elizabeth W Karlson
We are grateful to Dr. Baker and colleagues for their interest in our recent work and agree with their interpretation of our study that investigated weight change in the early rheumatoid arthritis (RA) period among women diagnosed with RA and matched comparators. As they point out, any weight loss and severe weight loss in the early RA or matched index period were both more common among those with RA than matched comparators. The authors suggest that this increased frequency of weight loss may exacerbate the obesity paradox for mortality among patients with RA...
January 17, 2018: Arthritis & Rheumatology
C H Brahe, C Dehlendorff, M Østergaard, J S Johansen, L M Ørnbjerg, K Hørslev-Petersen, K Stengaard-Pedersen, P Junker, T Ellingsen, H Lindegaard, I Hansen, T Lottenburger, S Jacobsen, A G Jurik, M L Hetland
OBJECTIVE: To investigate serum interleukin-6 (IL-6), serum chitinase-3-like protein-1 (YKL-40), and plasma vascular endothelial growth factor (VEGF) as measures of disease activity and predictors of clinical remission and radiographic progression in two early rheumatoid arthritis (RA) randomized controlled trials (RCTs). METHOD: Treatment-naïve patients with early RA (< 6 months' duration) and active disease, participating in two investigator-initiated RCTs, were treated according to a predefined treat-to-target algorithm aiming at inflammatory control, using methotrexate (MTX) + cyclosporine versus MTX + placebo (CIMESTRA study, n = 150, 5 year follow-up) or MTX + adalimumab versus MTX + placebo (OPERA study, n = 180, 2 year follow-up)...
January 16, 2018: Scandinavian Journal of Rheumatology
Maria Karolina Jonsson, Nina Paulshus Sundlisæter, Hilde Haugedal Nordal, Hilde Berner Hammer, Anna-Birgitte Aga, Désirée van der Heijde, Tore Kristian Kvien, Bjørg-Tilde Svanes Fevang, Siri Lillegraven, Espen Andre Haavardsholm
No abstract text is available yet for this article.
January 10, 2018: Annals of the Rheumatic Diseases
S B Gram, S Hess, P Ahlquist, P F Høilund-Carlsen, T Ellingsen
No abstract text is available yet for this article.
January 10, 2018: Scandinavian Journal of Rheumatology
Gunnel Östlund, Mathilda Björk, Ingrid Thyberg, Eva Valtersson, Annette Sverker
INTRODUCTION: The present study explored how women describe their use of situation-specific strategies when managing rheumatoid arthritis (RA). The aim was also to compare women's strategies with those of men, and see the extent to which they used the same strategies. METHODS: The data were collected using semi-structured interviews based on the critical incident technique. The sample consisted of women with early rheumatic arthritis (n = 34), and the results were compared with data reported in a previous study on men (n = 25) from the same cohort...
January 9, 2018: Musculoskeletal Care
Doyt L Conn, Athan Tiliakos, Gaobin Bao, Shuling Li, Kirk A Easley
Determine the effect of daily low divided or single daily dose of prednisone on the longitudinal change in the number of tender and swollen joints and HAQ scores in African Americans (AA) with early rheumatoid arthritis (RA) from the Consortium for the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis (CLEAR) 1 Registry. In a prospective, multicenter observational cohort study, AA with early RA were enrolled and followed longitudinally for up to 5 years. 345 were enrolled. The mean age at enrollment was 51 years and 82% were women...
January 3, 2018: Clinical Rheumatology
Laura Kuusalo, Kari Puolakka, Hannu Kautiainen, Anna Karjalainen, Timo Malmi, Leena Paimela, Marjatta Leirisalo-Repo, Vappu Rantalaiho
Adverse events (AEs) are common during disease-modifying antirheumatic drug (DMARD) treatment, but their influence on treatment results is unclear. We studied AEs in relation to disease activity in early rheumatoid arthritis (RA). Ninety-nine patients started intensive treatment with three conventional synthetic DMARDs (csDMARDs) and oral prednisolone, and were randomized to a 6-month induction treatment with infliximab or placebo. All AEs during the first 12 months of treatment were recorded. We scored each AE based on severity (scale 1-4) and defined the burden of AEs as the sum of these scores...
December 26, 2017: Clinical Rheumatology
Soo-Kyung Cho, Jiyoung Lee, Minkyung Han, Sang-Cheol Bae, Yoon-Kyoung Sung
BACKGROUND: Treatment with disease-modifying anti-rheumatic drugs (DMARDs) has raised concerns about the risk of malignancies in rheumatoid arthritis (RA) patients. However, the association between biologic DMARDs (bDMARDs) and malignancy in previous reports remains controversial. Therefore we aimed to estimate the incidence of malignancy in early RA patients and to evaluate the relative risk of malignancy with use of bDMARDs. METHODS: A retrospective cohort of incident RA patients was established using the Korean National Claims Database...
December 15, 2017: Arthritis Research & Therapy
Soo-Kyoung Cho, Dam Kim, Soyoung Won, Jiyoung Lee, Chan-Bum Choi, Jung-Yoon Choe, Seung-Jae Hong, Jae-Bum Jun, Tae-Hwan Kim, Eunmi Koh, Hye-Soon Lee, Jisoo Lee, Dae-Hyun Yoo, Bo Young Yoon, Sang-Cheol Bae, Yoon-Kyoung Sung
Background/Aims: To identify the factors associated with time to diagnosis after symptom onset in patients with early rheumatoid arthritis (RA). Methods: Early RA patients with ≤ 1 year of disease duration in the KORean Observational study Network for Arthritis (KORONA) database were included in this analysis. Patients were further divided into two groups according to the time to diagnosis from symptom onset: the early diagnosis group (time to diagnosis ≤ 1 year) and the late diagnosis group (time to diagnosis > 1 year)...
December 15, 2017: Korean Journal of Internal Medicine
Lynne M Feehan, Linda L Li, Heather A McKay
BACKGROUND: We used High Resolution - peripheral Quantitative CT (HR-pQCT) imaging to examine peri-articular bone quality in early rheumatoid arthritis (RA) and explore whether bone quality improved over 12-months in individuals receiving care consistent with practice guidelines. METHODS: A 1-year longitudinal cohort study (Baseline and 12-months) evaluating individuals with early RA compared to age/sex-matched peers. Personal demographic and health and lifestyle information were collected for all...
December 11, 2017: BMC Musculoskeletal Disorders
Laura A Ridgley, Amy E Anderson, Arthur G Pratt
PURPOSE OF REVIEW: Rheumatoid arthritis is a systemic disease of evolving immune dysregulation that culminates in joint destruction and disability. The principle by which pro-inflammatory cytokines may be therapeutically targeted to abrogate disease is well established, but has yet to translate into reliable cures for patients. Emerging insights into cytokine-mediated pathobiology during rheumatoid arthritis development are reviewed, and their implications for future treatment strategies considered...
March 2018: Current Opinion in Rheumatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"